116 related articles for article (PubMed ID: 20682978)
1. Expression and localization of e-cadherin in epithelial ovarian cancer.
Koensgen D; Freitag C; Klaman I; Dahl E; Mustea A; Chekerov R; Braicu I; Lichtenegger W; Sehouli J
Anticancer Res; 2010 Jul; 30(7):2525-30. PubMed ID: 20682978
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of E-cadherin-catenin complex in epithelial ovarian cancer.
Voutilainen KA; Anttila MA; Sillanpää SM; Ropponen KM; Saarikoski SV; Juhola MT; Kosma VM
J Clin Pathol; 2006 May; 59(5):460-7. PubMed ID: 16461565
[TBL] [Abstract][Full Text] [Related]
3. Immunoexpression of beta-catenin--E-cadherin complex in primary serous ovarian tumors.
Stawerski P; Wagrowska-Danilewicz M; Stasikowska O; Gottwald L; Danilewicz M
Pol J Pathol; 2008; 59(1):27-32. PubMed ID: 18655368
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical patterns for alpha- and beta-catenin, E- and N-cadherin expression in ovarian epithelial tumors.
Marques FR; Fonsechi-Carvasan GA; De Angelo Andrade LA; Böttcher-Luiz F
Gynecol Oncol; 2004 Jul; 94(1):16-24. PubMed ID: 15262114
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of the plasminogen activator inhibitor type-1 in epithelial ovarian cancer.
Koensgen D; Mustea A; Denkert C; Sun PM; Lichtenegger W; Sehouli J
Anticancer Res; 2006; 26(2C):1683-9. PubMed ID: 16617562
[TBL] [Abstract][Full Text] [Related]
6. Expression of EphA2 and E-cadherin in colorectal cancer: correlation with cancer metastasis.
Saito T; Masuda N; Miyazaki T; Kanoh K; Suzuki H; Shimura T; Asao T; Kuwano H
Oncol Rep; 2004 Mar; 11(3):605-11. PubMed ID: 14767510
[TBL] [Abstract][Full Text] [Related]
7. E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology.
Rubin MA; Mucci NR; Figurski J; Fecko A; Pienta KJ; Day ML
Hum Pathol; 2001 Jul; 32(7):690-7. PubMed ID: 11486167
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of dysadherin and E-cadherin expression in patients with head and neck cancer treated by radiation therapy.
Muramatsu H; Akimoto T; Maebayashi K; Kita M; Mitsuhashi N
Anticancer Res; 2008; 28(6B):3859-64. PubMed ID: 19192641
[TBL] [Abstract][Full Text] [Related]
9. E-Cadherin complex protein expression and survival in ovarian carcinoma.
Davidson B; Gotlieb WH; Ben-Baruch G; Nesland JM; Bryne M; Goldberg I; Kopolovic J; Berner A
Gynecol Oncol; 2000 Dec; 79(3):362-71. PubMed ID: 11104606
[TBL] [Abstract][Full Text] [Related]
10. Significance of adhesion molecules expression for estimation of serous ovarian cancer prognosis.
Ryabtseva OD; Lukianova NY; Shmurakov YA; Polishchuk LZ; Antipova SV
Exp Oncol; 2013 Sep; 35(3):211-8. PubMed ID: 24084461
[TBL] [Abstract][Full Text] [Related]
11. Expression of E-cadherin in human ductal breast cancer carcinoma in situ, invasive carcinomas, their lymph node metastases, their distant metastases, carcinomas with recurrence and in recurrence.
Jeschke U; Mylonas I; Kuhn C; Shabani N; Kunert-Keil C; Schindlbeck C; Gerber B; Friese K
Anticancer Res; 2007; 27(4A):1969-74. PubMed ID: 17649807
[TBL] [Abstract][Full Text] [Related]
12. CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish "MALOVA" Ovarian Cancer Study.
Høgdall EV; Christensen L; Kjaer SK; Blaakaer J; Kjaerbye-Thygesen A; Gayther S; Jacobs IJ; Høgdall CK
Gynecol Oncol; 2007 Mar; 104(3):508-15. PubMed ID: 17113137
[TBL] [Abstract][Full Text] [Related]
13. E-cadherin gene polymorphisms and haplotype associated with the occurrence of epithelial ovarian cancer in Chinese.
Li Y; Liang J; Kang S; Dong Z; Wang N; Xing H; Zhou R; Li X; Zhao X
Gynecol Oncol; 2008 Feb; 108(2):409-14. PubMed ID: 18035404
[TBL] [Abstract][Full Text] [Related]
14. E-cadherin and alpha-, beta-, and gamma-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusions.
Davidson B; Berner A; Nesland JM; Risberg B; Berner HS; Tropè CG; Kristensen GB; Bryne M; Ann Florenes V
J Pathol; 2000 Dec; 192(4):460-9. PubMed ID: 11113863
[TBL] [Abstract][Full Text] [Related]
15. Change of E-cadherin by hepatocyte growth factor and effects on the prognosis of hypopharyngeal carcinoma.
Kim CH; Kim J; Kahng H; Choi EC
Ann Surg Oncol; 2007 May; 14(5):1565-74. PubMed ID: 17294073
[TBL] [Abstract][Full Text] [Related]
16. [Expressions of E-cadherin in non-small cell lung cancer and it correlation with prognosis].
Qiao GB; Wu YL; Ou W; Yang XN; Zhong WZ; Lin JY; Zhao J; Xie D; Guan XY
Zhonghua Wai Ke Za Zhi; 2005 Jul; 43(14):913-7. PubMed ID: 16083620
[TBL] [Abstract][Full Text] [Related]
17. E-cadherin as a prognostic marker in human serous carcinomas of the ovary: an immunohistochemical analysis.
Dian D; Brüning A; Mylonas I
Arch Gynecol Obstet; 2011 Aug; 284(2):437-43. PubMed ID: 20803206
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
19. E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance.
Rakha EA; Abd El Rehim D; Pinder SE; Lewis SA; Ellis IO
Histopathology; 2005 Jun; 46(6):685-93. PubMed ID: 15910600
[TBL] [Abstract][Full Text] [Related]
20. Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer.
Mustea A; Pirvulescu C; Könsgen D; Braicu EI; Yuan S; Sun P; Lichtenegger W; Sehouli J
Cytokine; 2008 Apr; 42(1):77-84. PubMed ID: 18329282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]